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features can predict NB tumor behavior and outcome, but high-risk tumors, especially those in patients over the age of 18 months, are hard to cure. Despite maximally intensive, multimodality therapy, including stem cell transplant, less than 50 % of patients are cured, so more effective and less toxic therapies are greatly needed. There is growing interest in therapies that target particular genes, proteins and pathways that contribute to malignancy [1] [2] [3] , and increasing evidence suggests that members of the tropomyosin receptor kinase (Trk) family play important roles in NB behavior [4] [5] [6] [7] .
We and others have shown that TrkA, the receptor for nerve growth factor (NGF), is expressed on most favorable tumors, and the NGF/TrkA pathway may be involved in the spontaneous regression or differentiation seen in favorable NBs, especially in infants [8] [9] [10] [11] [12] . Conversely, TrkB and its primary ligand, brain-derived neurotrophic factor (BDNF), are expressed in many unfavorable NBs, and the autocrine activation of this pathway contributes to aggressive behavior, such as enhanced survival, invasion, metastasis, angiogenesis and drug resistance [13] [14] [15] [16] [17] [18] [19] . Therefore, targeting this pathway with selective Trk receptor inhibitors, alone or in combination with other agents, should be an effective and relatively nontoxic approach to treat aggressive NBs [2] .
Lestaurtinib (CEP-701, Cephalon, Inc.) was the first Trk inhibitor to be developed for the treatment of NBs [14, [20] [21] [22] . Indeed, this agent was used in a Phase 1 clinical trial for recurrent/refractory NBs [23] . Although 8/16 (50 %) of patients treated at a biologically effective dose had durable responses lasting more than 10 months on average [23] , lestaurtinib is no longer being supported for clinical applications. Newer agents have been developed that are more potent and selective for the Trk family receptors [24] [25] [26] , but none of these have been carried forward into clinical trials for NB. Thus, there is still a critical need for the exploration of Trk-selective inhibitors in NBs and other cancers with evidence of Trk activation.
We have evaluated the efficacy of a novel, Trk-selective inhibitor, GNF-4256, against TrkB-expressing NB cells in vitro and in vivo in a mouse xenograft model. GNF-4256 inhibits TrkB phosphorylation and the in vitro growth of TrkB-expressing NBs in a dose-dependent manner. Furthermore, GNF-4256 inhibits the growth of NB xenografts as a single agent, and it significantly enhances the antitumor efficacy of irinotecan plus temozolomide (Irino-TMZ). Our data strongly support the development of GNF-4256 or other Trk-selective inhibitors for the treatment of NB and other cancers with Trk activation.
Materials and methods

Compounds
GNF-4256 was designed and synthesized by the Genomics Institute of the Novartis Research Foundation (GNF) as a novel, selective and potent pan-Trk inhibitor. The antiproliferative effects of GNF-4256 were determined in Ba/ F3 assays where Ba/F3 cells were rendered TRKA, TRKB and TRKC dependent and IL-3 independent by overexpressing the constitutively active Tel-TRKA, Tel-TRB and Tel-TRKC fusion, respectively. In these assays, GNF-4256 was shown to inhibit Ba/F3-Tel-TRKA, TRKB and TRKC with an IC 50 less than 20 nM, while there was no activity in the parental Ba/F3 cells grown in the presence of IL-3 (15 nM for TrkA, 7 nM for TrkB, 2 nM for TrkC). Similar potency was obtained in biochemical assays using the Caliper method with recombinant TRKA, B and C kinase domains [27] . The biochemical kinase selectivity was evaluated by testing GNF-4256 on a panel of 59 kinases, and the cellular selectivity was evaluated on a panel of 36 tyrosine kinases (Supplemental Tables S1 and S2) . Overall, GNF-4256 showed very high selectivity for Trks, with only some marginal activity against ROS confirmed in the cellular assay (IC 50 = 3.8 μM). GNF-4256 was formulated in 0.5 % Methylcellulose + 0.5 % Tween-80 suspension in distilled water at concentrations of 4 or 10 mg/ml. Fresh batches of suspension were made for each week of in vivo dosing. Normal saline was used as the vehicle control. Irinotecan (Camptostar; Irino) and temozolomide (Temodar; TMZ) were obtained through the pharmacy at the Children's Hospital of Philadelphia (CHOP).
Cell lines
In vitro studies were performed using SY5Y-TrkB, a subclone of the SH-SY5Y NB cell line that was stably transfected with a TrkB expression vector [14, 22, 24] . The SY5Y parental cell line was used as a Trk-null control. Cells were grown in RPMI-1640 medium (Gibco) containing 10 % fetal bovine serum (Cellgro), 0.4 mg/ml Pen/ Strep (Gibco) and 0.3 mg/ml G418 (SY5Y-TrkB cells only, to select for TrkB expression) in 150 cm 3 Corning culture flasks. Cells were maintained at 37 °C, 5 % CO 2 and harvested using 0.2 % tetrasodium EDTA in phosphate-buffered saline (PBS). For in vivo studies, SY5Y-TrkB cells were grown and harvested as described above.
In vitro studies
To determine the efficacy and specificity of GNF-4256 for TrkB-expressing tumors, SY5Y Trk-null and SY5Y-TrkB cells were grown in 10 cm 3 dishes to 70-80 % confluency with standard culture medium. Cells were treated with a concentration of GNF-4256 (1-500 nM) for 1 h and then stimulated with the TrkB ligand, BDNF (100 ng/mL, PeproTech, Rocky Hill, NJ), for 15 min. Cells were then harvested for protein extraction. Trk expression analysis was performed via Western blot using anti-phospho-Trk antibody [Phospho-Trk, Tyr-490 antibody; Cell Signaling Technologies (CST), Danvers, MA] or anti-Pan-Trk antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Downstream signaling inhibition was analyzed using anti-phospho-AKT (CST) and anti-phospho-ERK1/2 antibodies (CST). Blots were reprobed with anti-AKT and anti-ERK1/2 antibodies (CST) to determine uniformity of loading.
Sulphorhodamine B (SRB) assays were performed to determine the effect of GNF-4256 on cell viability and growth. Cells were plated at 5 × 10 3 cells per well in 96-well Corning plates. Twenty-four hours later, cells were treated with varying concentrations of GNF-4256 for 1 h, followed by cell growth stimulation using 100 ng/ml BDNF. Cells were harvested at 24, 48 and 72 h post-stimulation. Cells were fixed, stained and quantified according to standard SRB protocols. All in vitro experiments were done in triplicate and performed at least three times.
Animals
Six-week-old athymic (nu/nu) mice were obtained from Jackson Laboratories. Mice were housed in a temperature and 12-h light-controlled environment at five animals per cage. We assessed toxicity by daily behavior observation, twice weekly weight measurements, and blood counts before and after treatment. Tissues of treated mice were assessed for gross toxicity post-killing. Abnormal tissues, if found, were examined microscopically. The Institutional Animal Care Committee of the Joseph Stokes, Jr. Research Institute at CHOP, approved the animal studies described.
In vivo studies
Animals were injected subcutaneously in the flank with 1 × 10 7 SY5Y-TrkB cells in 0.1 ml of Matrigel (BD Bioscience, Palo Alto, CA). Tumors were measured twice per week in three dimensions, and total volume was calculated by:
. Oral treatment with GNF-4256 and/or Irino-TMZ began when average tumor size reached 0.2 cm 3 (at least 10 mice per arm). Body weights were measured twice weekly, and drug doses were adjusted accordingly. GNF-4256 was administered twice daily (8 h apart), 7 days per week, by oral gavage at final concentrations of either 40 or 100 mg/kg. For combination studies, Irino was administered at 0.63 mg/ kg once daily, 5 days a week (Monday to Friday), by oral gavage. TMZ was given at a dose of 7.5 mg/kg once daily, 5 days a week, by oral gavage (Monday to Friday). The same doses of Irino and TMZ were used when administered in combination with GNF-4256. Irino and TMZ were resuspended in normal saline for oral gavage. The doses used for Irino and TMZ were based on previously published studies [28, 29] and our own experience with chemotherapeutic treatment of our xenograft mouse model. Drug administration continued twice daily, 7 days a week (GNF-4256) or once daily 5 days a week (Irino-TMZ) for 4 weeks, or until tumors reached 3 cm 3 . Retro-orbital and terminal bleeds were used for blood counts and pharmacokinetic studies.
Pharmacokinetic/pharmacodynamic studies For PK analysis, GNF-4256 was administered at 40 or 100 mg/kg BID for 2 weeks (30 animals per arm). At the end of the 2-week-long experiment, animals were killed at 1, 3, 8, 9 (1 h post-afternoon dose) and 24 h (16 h postafternoon dose) post-morning dose. Terminal blood and tumor samples were collected from three animals at each time point. Blood samples (~80 μl) were collected in heparinized tubes and centrifuged immediately to separate the plasma. The tumor samples were snap-frozen until analysis. Plasma and tumor samples were also collected from a group of animals that only received 1 day of dosing (both morning and afternoon dose) to establish Day 1 PK. These data were compared with the terminal PK to establish if changes in exposures had occurred during the twoweek period. The drug concentrations were determined using a liquid chromatography/mass spectrometry (LC/ MS/MS) method with a Zorbax SB-C8 analytical column (2.1 × 30 mm, 3.5 μm, Agilent Technologies Inc., Palo Alto, CA, USA). The lower limits of quantification were 1 ng/ml for plasma and 5 ng/g for tissue. Pharmacokinetic parameters were calculated by noncompartmental regression analysis using Phoenix WinNonlin 6.0 software (Pharsight, USA). The highest concentration (C max ) and the area under the concentration-time curve (AUC 0-24 h ) were reported.
Statistical analysis
A linear mixed-effects model was used to test the difference in the rate of tumor volume change over time between groups. The model included group, day and group-by-day interaction as fixed effects and included a random intercept and a random slope for each mouse. Event-free survival (EFS) curves were estimated using Kaplan-Meier method and compared using a log-rank test.
Results
Effect of GNF-4256 on TrkB-expressing SH-SY5Y NB cells in vitro
We first tested the efficacy of GNF-4256 in inhibiting TrkB phosphorylation in our SH-SY5Y-TrkB-transfected NB cell lines. In control SY5Y-TrkB cells, TrkB phosphorylation was seen at maximal intensity 15 min after BDNF addition. In the GNF-4256-treated samples, there was a dosedependent inhibition of ligand-induced phosphorylation (Fig. 1a) . The observed IC 50 was between 3 and 10 nM, and the IC 90 was between 30 and 100 nM concentrations, with complete inhibition by 200 nM.
Next, we tested the effect of GNF-4256 on parental (Trk-null) SY5Y and SY5Y-TrkB cells to determine its specificity and sensitivity to TrkB inhibition. Increasing concentrations of GNF-4256 had no effect on the growth of SY5Y Trk-null cells using either an RT-CES or SRB assay (data not shown). However, GNF-4256-treated SY5Y-TrkB cells displayed a dose-dependent decrease in cell growth, with increasing concentrations of GNF-4256 by both RT-CES (data not shown) and SRB assays (Fig. 1b) . Growth inhibition of SY5Y-TrkB cells was also seen in the absence of exogenous BDNF, but it was more modest (data not shown). There was a 50 % inhibition of cell growth at 50 nM GNF-4256, and growth levels were comparable to SY5Y-TrkB cells in the absence of ligand at 100 nM. These results established that GNF-4256 is a potent and selective inhibitor of TrkB-expressing NB cells.
Effect of GNF-4256 on SY5Y-TrkB NB xenografts
We next investigated the efficacy of GNF-4256 in inhibiting NB cell growth in vivo using a murine xenograft model. When the tumors grew to 0.2 cm 3 , we initiated treatment (either GNF-4256 at 40 or 100 mg/kg BID or with saline). We treated mice (10 per group) twice a day, 8 h apart, 7 days per week for 4 weeks (or until tumors exceeded 3 cm 3 ). GNF-4256 administered as a single agent at 40 or 100 mg/kg BID significantly slowed tumor growth compared to control animals (p < 0.0001 for both), but there was no significant difference between the two doses of GNF-4256 (Fig. 2a) . Similarly, GNF-4256 dosed at 40 or 100 mg/kg provided significant event-free survival (EFS) compared to control animals (p < 0.0025, p < 0.0001, respectively), but no significant difference was seen between the groups treated with different concentrations of GNF-4256 (Fig. 2b) .
We also examined the phosphorylation of TrkB in the vehicle (saline) and GNF-4256-treated tumors. Salinetreated NB xenografts showed substantial phosphorylation, similar to the same cells treated in vitro with BDNF, but all tumors treated with GNF-4256 at either 40 or 100 mg/kg (three samples shown for each dose) had dramatically reduced TrkB auto-phosphorylation (Fig. 2c) . To assess the exposure of GNF-4256 in the plasma and tumor tissues, we next performed a pharmacokinetic analysis. Animals were dosed for either 1 day (Day 1), or for 2 weeks (Day 14) to determine whether changes in exposure occurred over time. Plasma and tumor samples were collected at 1, 3, 8, 9 and 24 h post-dosing on Day 1 and Day 14 of treatment. 9 and 24-h levels were obtained after the second daily dosing. GNF-4256 was absorbed and distributed rapidly into tumor tissue with a T max of 1 h (Fig. 3) . GNF-4256 exposure increased under-dose proportionally from 40 mg/kg BID to 100 mg/kg BID: A 2.5-fold increase of dose resulted in 1.6-fold (plasma) to 1.9-fold (tumor) increase in AUC 0-24 h (Table 1) . Although the AUC 0-24 h at 100 mg/kg BID dose was higher than that at 40 mg/kg BID dose, the time of free plasma concentrations above the in vitro IC 50 of TrkB (approximately 18 h) on Day 14 was similar (Fig. 3a, b) , which could explain the similar in vivo tumor growth inhibition observed with both dose groups (Fig. 2) . Consequently, 40 mg/kg BID was established as a sufficient dosing regimen for our NB xenograft model.
Compared to the single-day treatment groups, the plasma and tumor exposures in the animals receiving 2 weeks of treatment were similar, suggesting GNF-4256 was not accumulated after multiple days of dosing (Fig. 3) . The tumor and plasma exposure were also similar, suggesting that GNF-4256 has low-to-moderate tumor Animals treated with GNF-4256 at either 40 or 100 mg/ kg BID had significantly slower-growing tumors than control animals (p < 0.0001 for both), but exhibited no significant difference between each other. b Effect of GNF-4256 on event-free survival (EFS). Animals dosed twice daily with 40 or 100 mg/kg GNF-4256 for 4 weeks, or until tumors reached 3 cm 3 , had significantly greater EFS over control animals (p < 0.0025, p < 0.0001, respectively). Again, no significant difference was observed between animals dosed with 40 and 100 mg/kg of GNF-4256. c Western analysis of TrkB phosphorylation in GNF-4256-treated tumors. In vitro control SY5Y-TrkB cells exhibited moderate levels of TrkB phosphorylation, which increases after 15 min of exposure to 100 ng/ml BDNF (lanes 1 and 2) . Similar levels of steady-state TrkB phosphorylation are observed in vehicletreated mouse xenografts, whereas mice treated with GNF-4256 at either 40 or 100 mg/kg exhibit almost complete inhibition of phospho-TrkB at 3 and 8 h post-treatment. No significant difference in inhibition is seen between xenografts from mice treated with 40 or 100 mg/kg GNF-4256 distribution (Fig. 3) . These observations of no accumulation and low-to-moderate tumor distribution were consistent with the PK properties (i.e., short half-life and low volume of the distribution) of GNF-4256 determined in an IV single-dose mouse PK study (data not shown). Importantly, no substantial toxicity was observed in either group.
Effect of combining GNF-4256 with Irino-TMZ in SY5Y-TrkB NB xenografts NB patients with recurrent or refractory disease are often treated using a combination of the chemotherapeutic agents, Irino and TMZ. To determine whether co-treatment with GNF-4256 would enhance the therapeutic efficacy of Fig. 3 a, (Fig. 4) . Growth inhibition reached baseline levels (comparable to no BDNF treatment) at 75 nM GNF-4256 alone, and this was similar to treatment with Irino-TMZ. Adding GNF-4256 to Irino-TMZ treatment decreased cell growth significantly below the control cell index, suggesting enhanced cell death with the combination. Based on these results, we wanted to determine whether we could achieve greater in vivo treatment efficacy using co-treatment of GNF-4256 with Irino-TMZ. We treated mice bearing NB xenografts with vehicle, GNF-4256, Irino-TMZ or GNF-4256 plus Irino-TMZ for either 4 weeks, or until tumor sizes exceeded 3 cm 3 . GNF-4256 was administered orally at 40 mg/kg twice daily, 7 days a week, and Irino-TMZ was administered orally once daily, 5 days a week.
Co-treatment of GNF-4256 with Irino-TMZ resulted in significant slowing of tumor growth (Fig. 5a ). The effects of either single-agent GNF-4256 or Irino-TMZ alone were significant compared to vehicle-treated tumors (p < 0.0003, p < 0.0001, respectively), but not significantly different from each other. The combination of GNF-4256 and Irino-TMZ was significantly better than either treatment alone (compared to GNF-4256, p < 0.0001, and to Irino-TMZ, p < 0.0071). Similarly, both single-agent GNF-4256 and Irino-TMZ-treated animals had a significantly better EFS compared to controls (p < 0.0375, p < 0.0095), although they were not significantly different from each other (Fig. 5b) . Also, the combination of GNF-4256 with Irino-TMZ was significantly better than either therapy alone (p < 0.0226 and p < 0.0331, respectively).
In the combination therapy with Irino-TMZ, we also monitored the plasma and tumor exposure of GNF-4256. The terminal plasma and tumor samples were collected at 1 and 4 h post-dose on the last day of treatment (steady state). Both plasma and tumor concentrations obtained from the single-agent treatment groups were similar to that from the combination treatment group, suggesting that exposure of GNF-4256 was not altered by co-administration of Irino-TMZ (Supplemental Table S3 ). The effect of GNF-4256 on the exposure of Irino-TMZ was not determined in this combination study.
These data suggest that singly administered GNF-4256 has antitumor efficacy similar to Irino-TMZ in treating TrkB-expressing NB xenografts, and it significantly enhances the efficacy of Irino-TMZ in a murine NB xenograft model without increasing toxicity. Furthermore, we saw no effect on animal weight or behavior, no obvious organ toxicity and no effect on blood counts, suggesting that GNF-4256 is not only effective, but also safe to administer as a Trk inhibitor.
Discussion
NBs are well known for having heterogeneous clinical behavior, from spontaneous regression or differentiation, to relentless progression despite intensive, multimodality therapy. Previously, we and others have demonstrated that the Trk family of neurotrophin receptors plays an important role in this behavior (reviewed in [4] [5] [6] [7] ). Expression of TrkA is prevalent on biologically favorable neuroblastomas, especially those from infants, and the NGF/TrkA pathway may be responsible for the spontaneous regression or differentiation seen in these tumors [8] [9] [10] [11] [12] . Conversely, TrkB and its ligand BDNF are expressed in biologically unfavorable tumors, especially those with MYCN amplification, and this autocrine survival pathway may contribute to enhanced survival, invasion, metastasis, angiogenesis and drug resistance [13] [14] [15] [16] [17] [18] [19] . As a result, there has been increasing interest in agents that selectively inhibit the TrkB pathway, either alone or in combination with other agents, to treat recurrent or refractory NBs.
We have shown previously that the Trk inhibitor, lestaurtinib (CEP-701 or related compounds), was effective at inhibiting TrkB autophosphorylation and NB growth in a mouse xenograft model [14, [20] [21] [22] . Furthermore, we showed that lestaurtinib, when delivered at biologically relevant doses, produced protracted responses and significantly inhibited NB growth with limited toxicity in a Phase I clinical trial [23] . Unfortunately, lestaurtinib is no longer being supported for clinical applications, so we are exploring novel, second-generation Trk inhibitors as targeted therapy for NBs.
GNF-4256 is a novel, selective pan-Trk inhibitor discovered by the Genomic Institute of the Novartis Research Foundation. GNF-4256 selectively inhibits all Trk receptors (TrkA, TrkB, TrkC) with similar potency at nanomolar concentrations, but no other receptor tyrosine kinases are inhibited at these levels. Furthermore, it is formulated as an oral agent, making it suitable for clinical administration. Thus, GNF-4256 is an ideal candidate for further investigation as a treatment for NBs and other tumors in which Trk family genes are oncogenic drivers.
We have demonstrated that GNF-4256 is a potent and selective inhibitor of Trk autophosphorylation and NB tumor growth both in vitro and in vivo, using our TrkB model. Furthermore, GNF-4256 had no effect on the Trknull parental SY5Y cells, demonstrating that the Trk pathway mediated its antitumor affect. Remarkably, GNF-4256 had similar antitumor potency to the combination of Irino and TMZ, a chemotherapy combination frequently used to treat patients with recurrent or refractory NB. Given that essentially no toxicity was seen in animals treated with 40 mg/kg of GNF-4256, this makes it an attractive agent for treating relapse patients. Moreover, combination therapy of GNF-4256 and Irino-TMZ significantly enhanced the antitumor efficacy over Irino-TMZ alone, presumably by blocking an important survival pathway and inhibiting the consequences of BDNF/TrkB overexpression, such as invasion, metastasis, angiogenesis and drug resistance [13] [14] [15] [16] [17] [18] [19] .
Although many high-risk NBs have overexpression of BDNF and TrkB, there are a variety of other tumors in children and adults with Trk gene activation. TrkA is activated by translocation with several partner genes in papillary thyroid cancer [30] [31] [32] [33] , as well as a subset of lung cancers [34] . It can also be activated by autocrine overexpression in breast, prostate and pancreatic cancers [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . TrkC is activated by translocation in infantile fibrosarcomas, congenital mesoblastic nephromas and secretory breast cancers [52] [53] [54] [55] [56] [57] , and it can also be activated by autocrine overexpression in medulloblastoma, nasopharyngeal cancer and medullary thyroid cancer [58] [59] [60] [61] [62] [63] . To date, TrkB is only activated by autocrine overexpression, in such diseases as anaplastic Wilms tumor, as well as colorectal, gastric, lung, ovarian and hepatocellular cancer [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . Indeed, because of its frequency of activation, TrkB has been proposed as a promising target for cancer therapy [74] . Interestingly, to date, Trk receptors are rarely activated by mutation, although Trk activation occurs in many of the tumors tested.
Thus, given the variety of different tumors showing activation of different Trk genes, targeting Trk receptors with a pan-Trk inhibitor would be of benefit for a variety of cancers in both children and adults. There have been limited trials with Trk inhibitors, at least in children, and so the side effects of inhibiting all Trk receptors is unknown, but the side effects of lestaurtinib in a Phase 1 clinical trial in NB patients were limited to mild, including reversible liver transaminase elevations [23] . Given that GNF-4256 and possibly other second-generation Trk inhibitors are more potent and specific for Trk genes relative to other tyrosine kinases, the further development of this agent and its use in Phase 1 clinical trials is certainly warranted.
